エリトラビシンIIは,卵巣がんにおける化学抵抗を逆転させ,アポトーシスを促進する末期オートファジー阻害剤として識別されている
Jing Mo1,2, Qiling Cai3, Shanshan Chen2,4
1Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.
iScience
|August 29, 2025
まとめ
エリトラビシンII (EL-19) は,エリトリーナ・クリスタ・ガリから派生し,末期オートファギーを阻害し,卵巣がんの治療を強化し,薬剤耐性を克服するための潜在的な戦略を提供します.
科学分野:
- 生物化学
- 薬理学について
- 腫瘍学
背景:
- ガン治療と薬剤耐性を克服するための有望な戦略です
- エリトリーナ・クリスタ・ガリ・リンの誘導体は,その潜在的な抗がん性について調査された.
研究 の 目的:
- エリトリーナ・クリスタ・ガリ・リンの誘導体を検知する.
- エリトラビシンII (EL-19) の自己死抑制剤としての有効性を卵巣がんモデルで評価する.
主な方法:
- エリトリナ・クリスタ・ガリ・リンの誘導体のスクリーニング
- 卵巣がん細胞系 (A2780とA2780/DDP) を用いたインビトロ試験
- オルガノイド実験とインビボ動物モデル
主要な成果:
- エリトラビシンII (EL-19) は,オートファギーの末期を力強く抑制し,オートファゴソーム- リソソーム融合を阻害した.
- EL-19は細胞増殖の抑制,卵巣がんのオルガノイド活性抑制,アポトーシスの誘導を含む抗癌効果を示した.
- EL-19はシスプラチン誘発の保護性オートファギーを効果的に阻害し,動物モデルでの併用療法では優れた抗腫瘍効果を示した.
結論:
- エリトラビシンII (EL-19) は,有意な抗がん性を持つ強力な後期オートファジー阻害剤である.
- EL-19は,卵巣がんにおける化学療法による保護性自閉症の克服に役立つ.
- EL-19 とシスプラチンとの併用療法では,有望な抗腫瘍効果が示されています.
関連する概念動画
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
The Intrinsic Apoptotic Pathway
6.8K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.8K
Delivery Pathways to the Lysosome
7.0K
Eukaryotic cells use different mechanisms to eliminate toxic waste obsolete and worn-out substances. Lysosomes play a pivotal role in this, and hence, these substances are carried to the lysosome from other parts of the cell and extracellular space through different pathways. The most elaborately studied pathways to the lysosome are the endocytic pathways.
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
7.0K
Autophagic Cell Death
3.5K
Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
3.5K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Electron Transport Chain: Complex I and II
15.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
15.0K


